VERV Deadline: VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Verve Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from August 9, 2022, to April 1, 2024, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the court by October 28, 2024, to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Verve Therapeutics made false or misleading statements regarding the Heart-1 Phase 1b clinical trial of VERVE-101, including the circumstances under which the trial would be halted [4]. - It is claimed that the company overstated the potential benefits of its proprietary lipid nanoparticle delivery system, leading to materially false and misleading statements about its business and operations [4].